Why the study?
Semliki Forest virus viral replicon particles have been widely used, but chimeric replicon particles offer distinct advantages due to their unique biological properties.
Does a novel three-plasmid packaging system for chimeric SFV/SIN VRPs improve gene delivery and expression in mice compared to standard SFV VRPs?
Does a novel three-plasmid packaging system for chimeric SFV/SIN VRPs improve gene delivery and expression in mice compared to standard SFV VRPs?
A novel chimeric SFV/SIN viral replicon particle system demonstrates higher yield and stronger in vivo gene expression than standard SFV VRPs, showing promise for vaccine and gene therapy applications.
Answers are grounded in this paper and cite their sources.
Novel chimeric VRP packaging system advances preclinical vector design; leaves open clinical translation and safety.
Semliki Forest virus (SFV) viral replicon particles (VRPs) have been frequently used in various animal models and clinical trials. Chimeric replicon particles offer different advantages because of their unique biological properties. We here constructed a novel three‐plasmid packaging system for chimeric SFV/SIN VRPs. The capsid and envelope of SIN structural proteins were generated using two‐helper plasmids separately, and the SFV replicon contained the SFV replicase gene, packaging signal of SIN, subgenomic promoter followed by the exogenous gene, and 3′ UTR of SIN. The chimeric VRPs carried luciferase or eGFP as reporter genes. The fluorescence and electron microscopy results revealed that chimeric VRPs were successfully packaged. The yield of the purified chimeric VRPs was approximately 2.5 times that of the SFV VRPs (1.38 × 10 7 TU/ml vs. 5.41 × 10 6 TU/ml) ( p < 0.01). Furthermore, chimeric VRPs could be stored stably at 4°C for at least 60 days. Animal experiments revealed that mice immunized with chimeric VRPs (luciferase) had stronger luciferase expression than those immunized with equivalent amount of SFV VRPs (luciferase) ( p < 0.01), and successfully expressed luciferase for approximately 12 days. Additionally, the chimeric VRPs expressed the RBD of SARS‐CoV‐2 efficiently and induced robust RBD‐specific antibody responses in mice. In conclusion, the chimeric VRPs constructed here met the requirements of a gene delivery tool for vaccine development and cancer therapy.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: